$TLSA

4 stories mentioning TLSA

Every FINWIRES story that references TLSA, newest first.

Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial

Tiziana Life Sciences (TLSA) has completed patient enrollment for the phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis.The trial enrolled 48 patients in the US who will receive one of two doses of intranasal foralumab or placebo over a 12-week period, to be followed by a six-month open label extension phase, the company said.Topline data from the trial is expected in late Q3, Tiziana added.Price: $1.73, Change: $+0.12, Percent Change: +7.45%

$TLSA

Sectors27d ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding about 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, Boston Scientific (BSX) shares gained 1.9% after the company said Tuesday a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3%.UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with a physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.8%.MetaVia (MTVA) shares surged 64% Tuesday, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

$BSX$MTVA$TLSA$URGN

Sectors27d ago

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In sector news, Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, the company said Tuesday. The round included participation from Thrive Capital, Index Ventures, JPMorgan Chase's (JPM) growth equity arm, Maverick Ventures, Y Combinator and others, the company said.In corporate news, Boston Scientific (BSX) shares gained 1.4% after the company said Tuesday that a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Relay Therapeutics (RLAY) shares climbed 5.2% after it said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3.7%.MetaVia (MTVA) shares were up 58% in Tuesday trading, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

$BSX$MTVA$RLAY$TLSA

Sectors27d ago

Sector Update: Healthcare Stocks Lean Lower Premarket Tuesday

Healthcare stocks were leaning lower premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly declining and the iShares Biotechnology ETF (IBB) down 0.3%.Relay Therapeutics (RLAY) shares were up more than 11% after the company said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Cullinan Therapeutics (CGEM) received the US Food and Drug Administration's orphan drug designation for its CLN-049 investigational therapy for the treatment of relapsed/refractory acute myeloid leukemia, the company said. Cullinan Therapeutics stock was up more than 2% pre-bell.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the biotechnology company said. Shares of Tiziana Life Sciences were up more than 2% premarket.

$CGEM$IBB$RLAY$TLSA$XLV